Rapid Clinical Updates: Updates on Anticoagulation for Hospitalists
Rounds move faster when anticoagulation calls are crisp. In this case-driven update powered by recent trials and guidelines, compare DOACs vs VKAs after bioprosthetic valve procedures (and apply caution with very early DOAC use), apply CAD/PCI de-escalation strategies and when DOAC alone suffices, prioritize warfarin for antiphospholipid syndrome, navigate ESKD choices with apixaban, time DOAC starts after AF stroke, and avoid routine post-stroke bridging - leaving with step-by-step pathways.
Availability
On-Demand
Expires on Dec 13, 2026
Cost
Member: $0.00
Non-Member: $95.00
Credit Offered
1 CME Credit
1 Participation Credit
  • Faculty
  • Accreditation
  • Recommended
Faculty
  • Jagriti Chadha, MD, MPH, FACP, SFHM
  • Scott Kaatz, DO, MSc, SFHM
    • Dr. Kaatz reports working as a consultant for Bayer Pharmaceuticals, Inari, Anthos, AstraZeneca, and Gilead Sciences, Inc.
  • Margaret Fang, MD, MPH
  • Ebrahim Barkoudah, MD, FACP, MPH, SFHM
  • Joseph Sweigart, MD, SFHM
  • Lily Ackermann, ScM, MD, FACS, SFHM

Faculty Disclosures
The individuals in control of content for this activity have no relevant relationships with ACCME-defined ineligible companies to disclose unless listed here. Any relevant relationships were mitigated prior to the start of this activity.

Accreditation Statement
The Society of Hospital Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Credit Statement
The Society of Hospital Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

IOS App Download Powered By